Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Learn more about:
Related Clinical Trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study Education, Immigration and HPV Vaccination: an Informational Randomized Trial Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Serial MRI Scans During Radiation Therapy A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Cisplatin+Pembrolizumab+RT in Vulvar Cancer Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery MR-HIFU for Recurrent Gynaecological Cancer Pelvic Floor Disorders in Survivors of Gynecologic Malignancies Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Validation of a Nutrition Screening Tool A Survivorship Care Plan for Gynaecological Cancer Patients Self-Advocacy Serious Game in Advanced Cancer Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) Chemoradiation-Induced Nausea and Emesis: Quality of Life A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies ChemoFx® PRO – A Post-Market Data Collection Study Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Image-Guided Gynecologic Brachytherapy Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Topical Imiquimod in Treating Patients With Recurrent Paget’s Disease of the Vulva Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox. The Impact of the “WOMAN-PRO II Program” on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence CaptHPV : Validation of the Method “CaptHPV” for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Effectiveness of an Individualized Symptom Education Program (ISEP) A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer OCT-AF Imaging of Pre-cancers of Vulva and Cervix Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer Sentinel Node Extended in Squamous Cell Vulvar Cancer Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva

Brief Title

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Official Title

Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy

Brief Summary

      RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who
      are undergoing radiation therapy to the pelvis. It is not yet known whether octreotide is
      effective for diarrhea.

      PURPOSE: Randomized phase III trial to determine the effectiveness of octreotide in
      preventing diarrhea in patients who are undergoing radiation therapy to the pelvis.
    

Detailed Description

      OBJECTIVES:

        -  Determine the effectiveness of octreotide in reducing acute treatment-related diarrhea
           in patients receiving external-beam radiotherapy to the pelvis.

        -  Determine the effectiveness of this drug in reducing chronic treatment-related bowel
           dysfunction in these patients.

        -  Determine the toxicity of this drug in these patients.

        -  Assess the importance that these patients attach to various measures of bowel function.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to prior anterior resection of the rectum (yes vs no), total planned
      cumulative dose of radiotherapy, including boost fields (4,500-5,350 cGy vs 5,351-6,000 cGy
      vs more than 6,000 cGy), use of concurrent fluorouracil (none vs bolus vs continuous
      infusion), use of concurrent leucovorin calcium (yes vs no), use of concurrent cisplatin (yes
      vs no), superior border of initial field (at or inferior to the L4-5 interspace vs superior
      to the L4-5 interspace), planned intracavitary brachytherapy (yes vs no), and primary site of
      disease (rectal cancer vs prostate cancer vs gynecological cancer vs other). Beginning no
      later than the fourth day of radiotherapy, patients are randomized to one of two treatment
      arms.

        -  Arm I: Patients receive short-acting octreotide subcutaneously (SC) on day 1 and
           long-acting octreotide intramuscularly (IM) on days 2 and 29.

        -  Arm II: Patients receive placebo SC on day 1 and IM on days 2 and 29. In both arms,
           treatment continues in the absence of unacceptable toxicity or the development of severe
           diarrhea.

      Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and
      then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.

      Patients are followed weekly for 4 weeks and then at 1 and 2 years.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Reduction of diarrhea as measured by NCI CTC version 2.0 weekly during pelvic radiotherapy

Secondary Outcome

 Reduction of patient-reported bowel dysfunction as assessed by the bowel function questionnaire weekly during radiotherapy, weekly for 4 weeks after radiotherapy, and 12 and 24 months after completion of radiotherapy

Condition

Cervical Cancer

Intervention

octreotide acetate

Study Arms / Comparison Groups

 octreotide + radiation
Description:  Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.
Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.
Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.
Patients are followed weekly for 4 weeks and then at 1 and 2 years.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

130

Start Date

April 2002

Completion Date

July 2006

Primary Completion Date

July 2006

Eligibility Criteria

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cancer in the pelvis

          -  Plan to receive continuous definitive or adjuvant external-beam radiotherapy to the
             pelvis or pelvis and para-aortic lymph nodes (total planned dose of 4,500-5,350 cGy)

               -  Entire pelvis must be encompassed by planned radiotherapy field (superior border
                  not inferior to the most inferior aspect of sacroiliac joints)

               -  Portions of rectum may have special blocking depending on disease site

               -  Planned treatment for once-daily radiotherapy 4-5 times a week (planned daily
                  dose 170-210 cGy)

               -  No planned split-course radiotherapy

               -  No planned interstitial brachytherapy prior to completion of external-beam
                  radiotherapy

               -  Planned intracavitary radiotherapy allowed

               -  No planned cytotoxic chemotherapy agents concurrently with radiotherapy except
                  fluorouracil with or without leucovorin calcium or cisplatin

               -  Entered on study before the third radiotherapy fraction

          -  No current or prior metastases beyond pelvic or para-aortic lymph nodes

          -  No grade 3 or greater diarrhea, rectal bleeding, or abdominal cramping prior to
             radiotherapy

          -  No incontinence of stool

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Renal:

          -  No chronic renal failure

          -  Creatinine less than 2 times upper limit of normal (for patients with history of renal
             disease)

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known allergy to octreotide

          -  No history of inflammatory bowel disease

          -  No other concurrent medical condition that would preclude study participation

          -  No history of cholecystitis unless prior cholecystectomy

        PRIOR CONCURRENT THERAPY:

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to the pelvis

        Surgery:

          -  See Disease Characteristics

          -  No prior abdominal-perineal resection, Hartmann procedure, or other surgical procedure
             resulting in non-functioning rectum
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

James A. Martenson, MD, , 



Administrative Informations


NCT ID

NCT00033605

Organization ID

NCCTG-N00CA

Secondary IDs

CDR0000069304

Responsible Party

Sponsor

Study Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

James A. Martenson, MD, Study Chair, Mayo Clinic


Verification Date

July 2016